Teva Pharmaceutical Industries Limited (NYSE: TEVA) is Down 23.22% for the YTD

Teva Pharmaceutical Industries Limited is currently trading at $50.40 per share, up 0.38% or $0.19. The stock is down 23.22% for the year after opening 2016 at around $65 per share. At its current price, the company has a market capitalisation of $46.03 billion and a price/earnings ratio of 33.64. The 52-week low range on this stock is $48.01 on the low end, and $66.55 on the high end. The 1-year target estimate price for the stock is $68.77 per share. If we turn our attention to the earnings and estimated earnings over the past 4 financial quarters, we see a close correlation between actual results and estimates. In Q2 2016 the actual earnings came in at $1.25 per share with estimated earnings of $1.20 per share. In Q1 2016 actual earnings were reported at $1.20 per share with estimated earnings at $1.17 per share. In Q4 2015 actual earnings were $1.28 and estimated earnings were $1.29. In Q3 2015, actual earnings were reported at $1.35 and estimated earnings at $1.28.

Revenues and earnings have also shown some interesting trends since 2013. In 2015, revenues were reported at $19.65 billion while earnings came in at $1.59 billion. In 2014, revenues of $20.27 billion were reported with earnings of $3.06 billion. In 2013, revenues of $20.31 billion were reported with earnings of $1.27 billion. In terms of recommendation trends, the vast majority of analysts in September rate the stock as either a strong buy or a buy option with a minority of analysts favouring a hold option. Much the same has held true since June of this year. If we look at the stock’s recommendation rating, it is currently rated at 1.9 on a scale of 1.0 (strong buy) to 5.0 (sell).

News from Teva Pharmaceutical Industries Limited 

The last couple of upgrades/downgrades for Teva Pharmaceutical Industries Limited indicate a mixed bag. On 18 July, HSBC securities upgraded the stock to a buy from a hold. On 15 July Goldman downgraded the stock to a neutral from a buy rating. On 4 May 2016, Credit Suisse issued a neutral rating on the stock, while on 19 February, Wells Fargo rated Teva Pharmaceutical Industries Limited as an outperform stock.